New incident report
Incident Report Number: 2020-2325
Registrant Reference Number: 2019-US-028837
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: UNITED STATES
Prov / State: OREGON
PMRA Registration No. PMRA Submission No. EPA Registration No. 2596-177
Product Name: Hartz Ultraguard Pro Triple Active Flea and Tick Shampoo for Dogs
Liquid
Yes
Unknown
Site: Animal / Usage sur un animal domestique
Animal's Owner
Dog / Chien
Beagle
1
Male
14
45
lbs
Skin
>1 wk <=1 mo / > 1 sem < = 1 mois
>8 hrs <=24 hrs / > 8 h < = 24 h
System
Persisted until death
No
No
Died
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On approximately 04-Oct-2019, a 14 year old, 45 pound, neutered, male, Beagle dog, in unknown condition, with unknown concomitant medical condition, was administered 1 dose of Hartz Ultraguard Pro Triple Active Flea and Tick Shampoo for Dogs (Methoprene / Phenothrin / Pyriproxifen) via the topical route by the animal owner. On approximately 05-Oct-2019, the dog exhibited brown colored, liquid vomit and anorexia. On approximately 06-Oct-2019, the dog exhibited weight loss. On 14-Oct-2019, the dog died at home and was buried. The dog was not evaluated by a veterinarian and no treatments were performed. No further information was received in this case.
Death
Assessment: The active ingredients in this product have a wide margin of safety in dogs and are present in low concentration. Mild GI upset may occur if a dog is able to ingest the product but signs of the severity and duration reported in this case are not expected. Other causes must be considered in this case including underlying cancer, organ failure, infectious disease, and GI foreign body obstruction. No veterinary care was sought so the cause of death remains unknown but it is unlikely to be related to product use. The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.